ClinicalTrials.gg

Program

QLS1410

A development code. Also written as “Dose 1 of QLS1410”, “Dose 2 of QLS1410” and “Dose 3 of QLS1410”.

Its studies are mostly in Hypertension · Hyperaldosteronism, led by Qilu Pharmaceutical.

Furthest: phase 2, since Mar 18, 20265 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical55 open or runningphase 2since Mar 18, 2026Aug 26, 2025Dec 2026phase 2 · NCT07489612

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 26, 2025First study: phase 1 study in Uncontrolled HypertensionFirst studyNCT07152444 · 78 planned · China
  2. Jan 7, 2026Phase 1 study in Uncontrolled HypertensionNCT07358858 · 12 planned
  3. Mar 18, 2026Phase 2 study in HypertensionPhase 2 reachedNCT07489612 · 260 planned · China
  4. Apr 19, 2026Phase 2 study in HyperaldosteronismNCT07550465 · 60 planned
  5. Nov 4, 2026Phase 2 study in Uncontrolled HypertensionNCT07927556 · 260 planned

Ahead

  1. Dec 2026Primary completion: phase 2 study in HypertensionNCT07489612
  2. Apr 2027Primary completion: phase 2 study in HyperaldosteronismNCT07550465
  3. Dec 2027Primary completion: phase 2 study in Uncontrolled HypertensionNCT07927556

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07927556Uncontrolled Hypertension2Not yet recruitingDec 2027260
NCT07550465Hyperaldosteronism2Not yet recruitingApr 202760
NCT07489612Hypertension · China2By invitationDec 2026260
NCT07358858Uncontrolled Hypertension1Not yet recruitingFeb 7, 202612
NCT07152444Uncontrolled Hypertension · China1Not yet recruitingMay 202678

How it is read

Names in the registry

  • “Dose 1 of QLS1410”, 2 entries
  • “Dose 2 of QLS1410”, 2 entries
  • “Dose 3 of QLS1410”, 2 entries
  • “QLS1410”, 2 entries
  • “QLS1410 (CYP11B2 inhibitor)”, 1 entry

Codes read as this program: QLS1410.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.